Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis : Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Strober, B. (Central Connecticut Dermatology Research)
Paul, C. (Toulouse University and INSERM Infinity)
Blauvelt, A. (Oregon Medical Research Center)
Thaçi, D. (University of Lübeck)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Lebwohl, M. (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica))
White, K. (UCB Pharma)
Vanvoorden, V. (UCB Pharma)
Deherder, D. (UCB Pharma)
Gomez, N.N. (UCB Pharma)
Eyerich, K. (University of Freiburg)
Universitat Autònoma de Barcelona

Fecha:	2023
Resumen:	Bimekizumab is a monoclonal IgG1 antibody that inhibits interleukin-17A/F. Bimekizumab is more efficacious than secukinumab over 1 year in the treatment of psoriasis. Objective: Evaluate the safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis. The BE RADIANT phase 3b randomized controlled trial consisted of a 48-week double-blinded period, where patients received bimekizumab (320 mg every 4 or 8 weeks) or secukinumab (300 mg weekly to Week 4, then every 4 weeks), and an open-label extension (OLE). From Week 48, all patients received bimekizumab in the OLE. At Week 48, more patients achieved complete skin clearance (PASI 100; modified non-responder imputation) with bimekizumab than secukinumab (74. 8% vs 52. 8%). PASI 100 responses were maintained to Week 96 in continuous bimekizumab patients (70. 8%); patients who switched from secukinumab to bimekizumab had increased rates at Week 96 (76. 6%). The most common adverse events were: nasopharyngitis, oral candidiasis, and urinary tract infection. Safety data were consistent with the known safety profile of bimekizumab. Limited racial diversity; overlap with the COVID-19 pandemic. High PASI 100 responses achieved with bimekizumab over 48 weeks were sustained through Week 96; secukinumab patients who switched to bimekizumab achieved similar responses by Week 96.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Bimekizumab ; Clinical trial ; Efficacy ; Open-label ; Plaque psoriasis ; Psoriasis ; Safety ; Secukinumab
Publicado en:	Journal of the American Academy of Dermatology, Vol. 89 Núm. 3 (september 2023) , p. 486-495, ISSN 1097-6787

DOI: 10.1016/j.jaad.2023.04.063
PMID: 37182701

10 p, 893.8 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados